Effects Of Oxandrolone Research Articles

Metformin reduces oxandrolone- induced depression-like behavior in rats via modulating the expression of IL-1β, IL-6, IL-10 and TNF-α

Oxandrolone (OXA) is an androgen and anabolic steroid (AAS) that is used to reverse weight loss associated with some medical conditions. One of the side effects of OXA is its potential to induce depressive symptoms. Growing evidence suggested that neuroinflammation and cytokines play crucial roles in sickness behavioral and associated mood disturbances. Previous studies showed that metformin attenuated neuroinflammation. This study investigated the potential protective role of metformin against OXA-induced depression-like behavior and neuroinflammation. Twenty- four Wistar male rats were randomly grouped into four groups: the control group (Control) received only vehicle; the oxandrolone group (OXA) received oxandrolone (0.28 mg/kg, i.p); the metformin group (MET) received metformin (100 mg/kg, i.p); and the oxandrolone / metformin group (OXA + MET) received both oxandrolone (0.28 mg/kg, i.p) and metformin (100 mg/kg, i.p). These treatments were administered for fourteen consecutive days. Behavioral tests to measure depression-like behavior were conducted before and after treatments. qRT-PCR was used to measure the relative expression of proinflammatory and anti-inflammatory cytokines in the hippocampus and hypothalamus. The results showed that oxandrolone induced depression-like behavior and dysregulated pro-/anti-inflammatory cytokines, while metformin attenuated these effects. These findings suggest that metformin is a potential treatment to reverse the depressive effects induced by oxandrolone that involve neuroinflammatory effects.

Low and high doses of oxandrolone promote pathological cardiac remodeling in young male rats

Oxandrolone (OXA) used in clinical practice, however, its misuse is frequent, including by adolescents pursuing an aesthetic goal. However, the impacts of noxious doses on the cardiovascular system remain unknown. AimTo investigate cardiac effects of OXA in low (LD) and high (HD) doses. MethodsMale Wistar prepubescent rats were separated into 3 experimental groups: control (CON), LD, and HD. Only the CON group received the carrier (carboxymethylcellulose, 0.5%), while the LD and HD groups received, respectively, 2.5 and 37.5 mg/kg/day of OXA via gavage for 4 weeks. The hemodynamic parameters (+dP/dtmax, −dP/dtmin, and Tau) and cardiac autonomic tonus were assessed. Hearts were retrieved for histological analyses and oxidative stress evaluation. Expression levels of calcium-handling proteins were measured by western blot. ResultsThe OXA treatment changed neither the cardiac contractility nor the cardiac autonomic tonus. However, cardiac hypertrophy, collagen deposition, and increased angiotensin-converting enzyme (ACE) expression were observed in a dose-dependent way. Also, the p-phospholamban (p-PLB)/PLB ratio was observed to decrease and increase, respectively, in the LD and HD groups; the sarcoplasmic/endoplasmic reticulum calcium ATPase 2a (SERCA2a)/PLB ratio being higher in both groups. OXA increased SOD1 expression and decreased catalase expression only in the LD group, and protein oxidation was increased in HD. ConclusionBoth doses of OXA could promote pathological cardiac remodeling, probably via increased ACE, and these effects were exacerbated in the HD treatment, but cardiac contractility was not affected regardless of the dose.

664 Risk Factors for the Development of Transaminitis in Pediatric Burn Patients Treated with Oxandrolone

Abstract Introduction Oxandrolone is an anabolic steroid that is the standard of care for burn patients experiencing hypermetabolism. Previous studies have demonstrated the benefits of oxandrolone, including increased body mass and improved wound healing. One of the common side effects of oxandrolone is transaminitis, occurring in 5–15% of patients, but little is known about associated risk factors with the development of transaminitis. A recent multicenter study in adults found that younger age and those receiving concurrent intravenous vasopressors or amiodarone were more likely to develop transaminitis while on oxandrolone. The purpose of this study was to determine the incidence and identify risk factors for the development of transaminitis in pediatric burn patients receiving oxandrolone therapy. Methods This was a multicenter, retrospective risk factor analysis that included pediatric patients with thermal burn injury (total body surface area [TBSA] > 10%) who received oxandrolone over a 5-year time period. The primary outcome of the study was the development of transaminitis while on oxandrolone therapy, which was defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >100 mg/dL. Secondary outcomes included mortality, length of stay, and change from baseline ALT/AST. Results A total of 55 pediatric patients from 5 burn centers met inclusion criteria. Of those, 13 (23.6%) developed transaminitis, and the mean time to development of transaminitis was 17 days. Patients who developed transaminitis were older (12 vs 6.4 years, p = 0.01) and had a larger mean %TBSA (45.9 vs 34.1, p = 0.03). The odds of developing transaminitis increased by 23% for each 1 year increase in age (OR 1.23, CI 1.06–1.44). The use of other concurrent medications was not associated with an increased risk of developing transaminitis. Renal function and hepatic function was not associated with the development of transaminitis. There was no significant difference in length of stay and mortality. Conclusions Transaminitis occurred in 23.6% of our study population and was associated with patients who were older and had a larger mean %TBSA burn. Older pediatric patients with larger burns who are receiving oxandrolone should be closely monitored for the development of transaminitis. Applicability of Research to Practice Future research is needed to identify appropriate monitoring and management of transaminitis in oxandrolone-treated pediatric burn patients.

Effects of Oxandrolone on Cardiometabolic Health in Boys With Klinefelter Syndrome: A Randomized Controlled Trial.

Klinefelter syndrome (KS) is a common condition in males, resulting in androgen deficiency and cardiometabolic diseases. These interrelated conditions may be present in prepubertal boys with KS. To determine whether supplemental low-dose androgen has a beneficial effect on body composition in prepubertal boys with KS. We conducted a secondary analysis of a randomized, double-blind, placebo-controlled clinical trial in 93 boys with KS aged 4 to 12 years. Oral oxandrolone (Ox) 0.06 mg/kg/d or placebo for 2 years. The primary outcome was percent body fat standard deviation score (%BF SDS) at 2 years. Secondary outcomes included additional measures of cardiometabolic health and safety. The %BF SDS at 2 years was significantly lower in the treatment (0.29 ± 0.76 SDS) compared with placebo group (0.81 ± 0.72 SDS) after adjusting for age and baseline %BF SDS (95% confidence interval for the difference between means -0.86 to -0.19 SDS, P = 0.009). Ox resulted in lower triglycerides (P = 0.043), but also lower high-density lipoprotein (HDL) cholesterol (P < 0.001) and a more rapid advancement in bone age (P = 0.011). Ox has positive effects on measures of cardiometabolic health in prepubertal boys with KS; however, it does lower HDL cholesterol and advance bone age.

The effects of oxandrolone on genital development in uncomplicated growth retardation

Oxandrolone therapy of children with uncomplicated growth retardation caused a marked increase in penile growth. The penile length percentile also showed a significant increase at the end of the therapy. Although the older boys fell into lower percentiles than the younger boys, it appears that they showed significant penile catch-up growth. Oxandrolone therapy did not appear to cause testicular growth impairment in the majority of the boys but in a few there was a temporary delay in growth.

The Effect of Oxandrolone on the Endocrinologic, Inflammatory, and Hypermetabolic Responses During the Acute Phase Postburn

Postburn long-term oxandrolone treatment improves hypermetabolism and body composition. The effects of oxandrolone on clinical outcome, body composition, endocrine system, and inflammation during the acute phase postburn in a large prospective randomized single-center trial have not been studied. Burned children (n = 235) with >40% total body surface area burn were randomized (block randomization 4:1) to receive standard burn care (control, n = 190) or standard burn care plus oxandrolone for at least 7 days (oxandrolone 0.1 mg/kg body weight q.12 hours p.o, n = 45). Clinical parameters, body composition, serum hormones, and cytokine expression profiles were measured throughout acute hospitalization. Statistical analysis was performed by Student t test, or ANOVA followed by Bonferroni correction with significance accepted at P < 0.05. Demographics and clinical data were similar in both groups. Length of intensive care unit stay was significantly decreased in oxandrolone-treated patients (0.48 +/- 0.02 days/% burn) compared with controls (0.56 +/- 0.02 days/% burn), (P < 0.05). Control patients lost 8 +/- 1% of their lean body mass (LBM), whereas oxandrolone-treated patients had preserved LBM (+9 +/- 4%), P < 0.05. Oxandrolone significantly increased serum prealbumin, total protein, testosterone, and AST/ALT, whereas it significantly decreased alpha2-macroglobulin and complement C3, P < 0.05. Oxandrolone did not adversely affect the endocrine and inflammatory response as we found no significant differences in the hormone panels and cytokine expression profiles. In this large prospective, double-blinded, randomized single-center study, oxandrolone shortened length of acute hospital stay, maintained LBM, improved body composition and hepatic protein synthesis while having no adverse effects on the endocrine axis postburn, but was associated with an increase in AST and ALT.

Effects of Oxandrolone on Outcome Measures in the Severely Burned: A Multicenter Prospective Randomized Double-Blind Trial

Effects of Oxandrolone on Outcome Measures in the Severely Burned: A Multicenter Prospective Randomized Double-Blind Trial

Effects of Oxandrolone on Outcome Measures in the Severely Burned: A Multicenter Prospective Randomized Double-Blind Trial

Effects of Oxandrolone on Outcome Measures in the Severely Burned: A Multicenter Prospective Randomized Double-Blind Trial

The Effects of Oxandrolone and Exercise on Muscle Mass and Function in Children With Severe Burns

Severe burns are associated with a significant loss of muscle and strength. Studies have reported that oxandrolone improves lean body mass in muscle-wasting conditions. Also shown previously in burned children is that an exercise program increases lean body mass and muscle strength. We hypothesized that oxandrolone, in combination with exercise, would increase lean body mass and muscle strength in severely burned children more than oxandrolone alone or exercise alone. Fifty-one burned children (> or = 40% total body surface area burned) were randomly assigned to receive oxandrolone alone (0.1 mg/kg per day orally; n = 9), oxandrolone and exercise (n = 14), placebo and no exercise (n = 11), or placebo and exercise (n = 17). Administration of oxandrolone was started at discharge and continued until 1 year after burn. The 12-week exercise training program was started 6 months after burn. Serum hormones, lean body mass, muscle strength, and peak cardiopulmonary capacity were assessed at 6 (baseline) and 9 months after burn. Data were analyzed using a 1-way analysis of variance, and significance was set at P < .05. The mean percentage of change or increase in weight and lean body mass in the oxandrolone and exercise group was significant compared with placebo and exercise, as well as with the oxandrolone alone group or placebo and no exercise group. Furthermore, lean body mass was significantly improved in the oxandrolone and exercise, oxandrolone alone, and placebo and exercise group compared with the group only receiving placebo. Muscle strength significantly increased in oxandrolone and exercise, placebo and exercise, and the oxandrolone alone group when compared with the placebo and no exercise group. The peak cardiopulmonary capacity was significantly higher in both exercise groups. Insulin-like growth factor 1 was significantly increased in the oxandrolone alone group compared with placebo and exercise and placebo and no exercise. Both exercise groups showed significant changes in insulin-like binding-protein-3 when compared with groups without exercise. Oxandrolone, in combination with exercise, is beneficial in severely burned children, thus improving their rehabilitation.

The effects of oxandrolone and exercise on muscle mass and function in severely burned children

The effects of oxandrolone and exercise on muscle mass and function in severely burned children

A Phase III randomized study comparing the effects of oxandrolone (Ox) and megestrol acetate (Meg) on weight (wt), lean body mass (LBM) and quality of life (QOL) in solid tumor patients (pts) receiving chemotherapy (chemo)

18546 Background: Involuntary wt loss is a significant problem in pts with cancer and may lead to a decline in QOL, limit treatment options and reduce survival. Wt loss in these pts disproportionately represents a loss of muscle mass. Meg, a synthetic progesterone derivative, promotes wt gain mostly through an increase in adipose tissue rather than in LBM. Ox is a potent oral anabolic steroid with minimal androgenic activity which promotes wt gain primarily through increased LBM. Methods: Prospective, randomized phase III trial comparing the effects of Ox and Meg on wt, body composition and QOL in pts with solid tumors and wt loss receiving chemo. Body composition was serially assessed by Bioelectrical Impedance Analysis. QOL was evaluated with the FACT-G and the Anorexia/Cachexia subscale (FAACT). Eligibility: age ≥18; PS: 0–2; life expectancy ≥6 mos; near normal organ function; and progressive wt loss on chemo. Ineligibility: full dose anticoagulation; hormonally responsive or hematologic malignancies; and ongoing or planned treatment with corticosteroids (antiemetic use allowed), estrogens or progestins. The primary endpoint was LBM after 12 wks of drug therapy. Study design allowed 90% power for detecting a 1.5 kg difference between treatment groups using a 5% two-sided level of significance. A max of 155 pts were to be accrued. An interim analysis was planned after 62 pts had completed 12 wks on study. Results: As of 12/05, 74 pts have been accrued (72 eligible): median age 64 yrs, 42% females and 62% stage 4 disease. 25 pts (arm 1:8, arm 2:17) have completed 12 wks of therapy and 20 remain on study. 76 Grade 3/4 toxicities (arm 1:23, arm 2:53) and 1 grade 5 arrhythmia (arm 2) have been recorded. Accrual is ongoing and differing trends in wt gain and body composition between arms are emerging. Conclusions: This is the first and only trial comparing these two commonly utilized therapies for cancer-related anorexia/cachexia. Differences in efficacy, particularly effects on LBM, QOL and toxicity which emerge from this trial are likely to influence symptom management standards of care in the oncology community. Supported by Savient Pharmaceuticals and NCI grant 1 U10 CA81851. No significant financial relationships to disclose.

Reversal of COPD-Associated Weight Loss Using the Anabolic Agent Oxandrolone

Weight loss is a common complication of COPD, associated with negative outcomes. Weight restoration has been associated with improved outcomes. The effects of oxandrolone, an adjunct to help restore weight, were evaluated in patients with COPD. Prospective, open-label, 4-month clinical trial. Twenty-five community-based pulmonary practices throughout the United States. A primary pulmonary diagnosis of moderate-to-severe COPD as defined by FEV1 < 50% of predicted and FEV1/FVC ratio < 0.7, along with significant involuntary weight loss (weight < or = 90% ideal body weight). Oral oxandrolone, 10 mg bid. Body weight, body composition (bioelectric impedance analysis), spirometry, and 6-min walking distance were measured. Data for 82 patients at 2 months and 55 patients at 4 months are presented. At month 2, 88% of patients had gained a mean +/- SD of 6.0 +/- 4.36 lb (p < 0.05) and 12% had lost a mean of 1.7 +/- 2.15 lb (not statistically significant [NS]). At month 4, 84% had gained a mean of 6.0 +/- 5.83 lb (p < 0.05) and 16% had lost a mean of 1.8 +/- 1.74 lb (NS). Month 4 bioelectric impedance analysis showed the weight to be primarily lean tissue, with a mean increase in body cell mass of 3 +/- 2.6 lb (p < 0.05), and a mean increase in fat of 1.2 +/- 4.6 lb (NS). Oxandrolone is an effective adjunct to facilitate weight restoration in patients with COPD-associated weight loss. Weight gain is primarily lean body mass. Oxandrolone was relatively well tolerated and, therefore, should be a consideration in the comprehensive management of patients with COPD and weight loss.

Effects of oxandrolone and L-glutamine on body weight, body cell mass, and body fat in patients with HIV infection-preliminary analysis

Effects of oxandrolone and L-glutamine on body weight, body cell mass, and body fat in patients with HIV infection-preliminary analysis

Treatment of constitutional delay of growth and puberty with oxandrolone compared with growth hormone.

The effects of oxandrolone or biosynthetic human growth hormone (r-hGH) on the growth of 26 boys with constitutional delay of growth and puberty were studied. Both regimens increased growth rate twofold, oxandrolone to a greater extent than r-hGH. We conclude that oxandrolone is a more effective method of increasing growth rate in such children.

Effect of Growth Hormone and Oxandrolone Singly and Together on Growth Rate in Girls with X Chromosome Abnormalities

The linear growth effects of oxandrolone, human growth hormone, and Ox+hGH were compared in six girls, age 11 to 15 years, with X chromosome abnormalities (three with X,O karyotype, three with Turner syndrome variants). Over six successive three-month periods, the patient received either no treatment, Ox, hGH, or Ox+hGH. The data demonstrate a significant ( P

Mass spectrometric anaysis of urinary nitrogen from growth hormone deficient children administered glycine-15N+

Five children deficient in growth hormone were treated with oxandrolone and human growth hormone. Average nitrogen retained was calculated from nine day balance data. During some balance periods, nitrogen retention was calculated by determination of 15N labeled glycine, as reported in this article. Twenty milligrams of 15N in excess of the natural abundance was administered orally. Urines were collected prior to, as well as after, administration of glycine-15 N and were analyzed for 15N by mass spectrometry. The percentage of 15N ranged up to 0.449% for collection over a 24 hour period, compared with 0.364% from control samples without excess 15N. These 15N data, like those from nitrogen balance, show the stimulating effects of oxandrolone and human growth hormone in the group as a whole.

Triglyceride removal efficiency and lipoprotein lipases: Effects of oxandrolone

Very low density lipoprotein triglyceride turnover rate, fractional turnover rate, and half-life were studied using Glycerol −3H to label VLD-TG in 16 patients with familial Type IV hyperlipoproteinemia. The patients were maintained on an isocaloric diet with determination of triglyceride turnover after 2 wk of placebo, and a second determination after 2 wk of Oxandrolone (an anabolic-androgenic synthetic steroid). On placebo, mean very low density lipoprotein triglyceride (VLD-TG) was 539, falling on Oxandrolone to 254 mg 100 ml ( p < 0.05). Mean half-life ( T 1 2 ) was 10.3 hr on placebo and was shortened to 5.2 hr on drug ( p < 0.05). The fractional turnover rate (FTR) on placebo was 0.104 ± 0.016 hour −1, and rose to 0.166 ± 0.016 on drug ( p < 0.05). Mean turnover rate (TR) rose slightly from 17.6 mg/kg/hr on placebo to 19.04 mg/kg/hr on Oxandrolone. Both postheparin lipolytic activity (PHLA) and postheparin triglyceride lipase (TGL) were appreciably increased on drug, rising respectively from 0.297 μeq FFA/ml/min and 11.7 mμeq FFA/ml/hr (on placebo) to 0.396 and 23.7 (on drug). The changes (Δ) in VLD-TG on Oxandrolone correlated with Δ T 1 2 (R = 0.761) and with Δ FTR (R = −0.532). Oxandrolone may lower very low density lipoprotein triglyc eride by substantially increasing fractional turnover rate and shortening half-life while slightly augmenting turnover rate and improving efficiency of VLD-TG removal.

Effects of oxandrolone on plasma triglycerides and postheparin lipolytic activity in patients with types III, IV, and V familial hyperlipoproteinemia

Effects of Oxandrolone on plasma lipids, post-heparin lipases, fasting free fatty acids, glucose and insulin were studied in twenty patients with Types III, IV, and V hyperlipoproteinemia. Triglycerides fell significantly in 14 of 20 patients on short term therapy, and in an additional four patients on prolonged therapy. The fall in triglycerides was associated with a qualitative decrease in both chylomicron and prebeta- lipoprotein concentrations on paper lipoprotein electrophoresis. There were concurrent major increases in postheparin lipolytic activity without uniform changes in free fatty acids, glucose or insulin. Marked stimulation of postheparin lipolytic activities and increased peripheral triglyceride hydrolysis may in part account for the triglyceride lowering effect of oxandrolone.